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ABSTRACT 




Lithium, a popular drug for treating mental health disorder has shown promising effect in 
recent research on traumatic brain injury (TBI). The mechanism of lithium for treating 
bipolar mood disorder is still not properly understood, but recent studies showed that 
lithium is neuroprotective in TBI. In my thesis, the neuroprotective effects of lithium 
were examined in primary neuronal culture and mild blunt injury using rodent model of 
Lateral Fluid Percussion Injury (LFPI). At first determination of the 
neuroprotective/toxicity effects of lithium in neuronal culture was done and observed that 
0.5 - 1.0 mM concentrations were found to be neuroprotective as per cell viability assay. 
This optimized 1.0 mM lithium was then administered to injured animals to evaluate if 
lithium can restore the injury at day 1, 3, and 7 post-TBI. Fluorescent labeled tracer (2000 
kDa) was also deposited in the CSF directly to trace the time-dependent recovery of the 
damaged CSF-subarachnoid circulation by lithium. Tracer level as seen in the scanned 
images of the treated tissue sections, indicated the amount of lithium in blood circulation, 
supporting the theory that more amount of tracer indicates more leakage of the tracer due 
to rupture of Blood Brain Barrier (BBB) which can be caused by the injury. 
Quantification of Cresyl Violet labeled neurons in brain tissue sections shows an increase 
in neuronal cell number when treated with lithium post injury. The data collected by me 
for this thesis, supports the theory that lithium protects neurons against excitotoxicity 
effects of various chemicals, resulted by traumatic brain injury. 
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The main objective of this thesis is to explore the less-known applications of lithium as a drug 
other than mental health. In recent studies, lithium has shown promising effects after traumatic 
brain injury (TBI). For this thesis, the therapeutic dosage of Lithium for animal usage will be 
determined (aim 1) in cell culture studies with and without glutamate injury. In the animal 
model, histology study will be performed to observe the neuroprotective effect of Lithium 
after mild traumatic brain injury (aim 2). Finally, this thesis will discuss the idea of a few 




1.2 Traumatic Brain Injury (TBI) 
 
Depending on the cause, brain injury can be broadly classified as Traumatic Brain Injury or 
TBI and non-traumatic brain injury. 
 
Figure 1.1 : According to Brain Injury Association of Massachusetts, depending on the amount of force that impacts 




TBI happens when a sudden, violent blow jolts the head or when an object pierces the skull and 







Figure 1.2 Traumatic brain injury is caused by an external physical force that may produce a diminishes or 
altered state of consciousness and which results in an impairment of cognitive abilities or physical functioning. 
(North Dakota Brain Injury Network) 





According to the American Association of Neurological Surgeons, around 1.5 million TBI 
cases occur every year in US alone among which around 50,000 cases lead to death and 
estimated 80,000-90,000 causes lifelong disability. Approximately 3.1 million people 







Figure 1.3 The American Association of Neurological Surgeons reports that around 1.5 million TBI cases occur 
each year in the United States, around 50000 of these lead to death. 
Source : [2] 
 
 
Acute TBI can be classified into two injury phases - primary and secondary[3]. Primary injury 
is the direct injury following the trauma. This phase is characterized by concussion, direct 
neural damage, herniation of important brain structures which finally leads to secondary injury 
through progressive biochemical interactions. Primary injury cannot be avoided but the 
secondary injury can be contained to a certain limit by taking precautionary measures and with 
proper treatment. A cascade of biochemical processes is involved in the secondary phase - 
rapid release of excitotoxins like glutamate and aspartate which in turn act on N-methyl-D- 
aspertate or NMDA channel altering permeability of cell membrane, increase in intracellular 
calcium and calcium-modulated proteins like calcineurin and calmodulin. NMDA activation 
also increases the sodium level in intracellular spaces. All together helps in fragmentation of 
the axon [4]. Excessive release of potassium from cells are absorbed by astrocytes restricts the 




-ed and not limited to brain cells, also causes multiple organ failure. Major biochemical changes 
after brain injury involves growth factors, catecholamines, neurokinins, cytokines, and 
chemokines. 
 
Figure 1.4 : TBI is a modulator of various neurological signaling pathway. The above image is showing the chemical 
changes and possible targets in the secondary injury post TBI. 




1.3 Uses of Lithium as a drug 
 
Lithium (Li) silvery-white alkaline chemical material with atomic mass number 3, is the 
lightest metal known which also lightens your mood. Lithium has many uses - as a chemical its 
most popular use is in manufacturing of batteries and aircrafts; as a drug, it is widely used for 
treatment for bipolar disorder to stabilize the wild mood swings [6]. Lithium is used to treat 
manic episodes of bipolar disorders which includes hyperactivity, poor judgement, insomnia, 
aggression, and anger. It helps to lessen the intensity of manic episodes of this illness. It is also 
used for schizophrenia disorder and major depressive disorder (MDD), only after failure of 






Molecular mass 7 Da 
Protein binding 0% 
Oral bioavailability Immediate release 95% - 100% 
 
Modified release 60% - 90% 
Therapeutic serum concentration 0.6-1.2 mEq/L 
Half-life (therapeutic) 12 – 27 hours 
Toxic dose (acute poisoning) >1g elemental Li 
 
 
Figure 1.5 Physiochemical and Toxicokinetic Properties of Lithium 




Despite Lithium’s huge popularity, the physiologic role and its mechanism are not well 
understood [8]. Lithium's physiologic role is unknown, and its mechanism is not well 
understood; however, some proposed mechanisms include [9]: 
• Modulation of neurotransmission - Dopamine pathway[9-11]: 
 
In the nervous system dopamine works as an excitatory neurotransmitter which 
plays important roles in motor control, memory, reward, executive functions, sleep, 
learning etc. The cyclical dysregulation theory [12, 13] postulates that the elevation 
of dopamine neurotransmission during mania causes downregulation of dopamine 
receptors which ultimately results in decreasing dopamine neurotransmission 
associated with clinical depression. Postsynaptic activation of dopamine is mediated 
by G-proteins (stimulates second messenger systems like adenyl cyclase, cAMP) 
coupled receptors or GPCR. Lithium decreases presynaptic dopamine activity and 
inactivates the subunits of dopamine associated G proteins, thus maintaining the 
equilibrium between active and inactive subunits. This mechanism of Lithium 
helps in reducing excitatory neurotransmission in the brain. 
• Modulating neurotransmission - Glutamate pathway [9, 10, 14]: 
 
Glutamate, another excitatory neurotransmitter, causes excitotoxicity in increased 
levels. NMDA is a subtype of glutamate receptor which can be acutely simulated 
by lithium, thus increasing glutamate availability in postsynaptic neurons. After 
chronic administration, lithium enhances inhibitory neurotransmission by 
downregulating NMDA receptors which in turn inhibits myoinositol second 




maintains signal efficiency by production of two postsynaptic second messenger 
system pathways on Inositol triphosphate (IP3) and Diaglycerol (DAG) to modulate 
neurotransmission and regulate gene expression. Indirectly, lithium reduces 
glutamate activity by decreasing dopamine activity. 
• Modulating neurotransmission - GABA pathway [10, 14]: 
 
GABA is an inhibitory neurotransmitter which indirectly modulates dopamine and 
glutamate levels in the nervous system. Bipolar patients show deficiency or lower 
levels of GABA, thus postulating that GABA can result in excitatory toxicity. 
Lithium increases GABA level in cerebrospinal fluid by facilitating GABA release 
at presynaptic level and upregulating GABA-B receptors at postsynaptic level. 
Increased level of GABA reduces glutamate and downregulates NMDA receptors. 
• Modulating neurotransmission - Myoinositol pathway [14]: 
 
Phosphoinositides (PI) are precursors for many molecules that play an important 
role in CNS neurotransmission. Phosphoinositide helps in production of myoinositol 
with the help of ImPase and IPPase, which are then used to synthesize PIs. 
Myoinositol levels are found to be increased in patients with mania and depression. 
Lithium inhibits ImPase and IPPase reducing myoinositol level and this decreases 
the production of PI. Myoinositol levels are unaffected by lithium in euthymic 




• Modulating gene expression - cellular pathways [14]: 
 
a. Protein Kinase C (PKC), Myristoylated Alanine-Rich C Kinase Substrate 
(MARCKS) and Glycogen Synthase Kinase 3 (GSK3) are linked with mania. 
Lithium inhibits PKC and its downstream target MARCKS which has 
antimanic effects. GSK -3 is an enzyme which is involved in gene transcription 
and synaptic elasticity. GSK-3 activates due to chronic stress like mania. 
Lithium has shown inhibitory effects on GSK-3 thus maintaining the balance of 
brain chemistry. 
b. Lithium also inhibits the sodium-inositol transporter at the cellular level which 
reduces availability of myoinositol. 
c. Consistent finding of elevation of intracellular calcium concentration which 
plays role in neurotransmission, gene expression, metabolism, and cellular 
integrity, may mark an illness state. Myoinositol pathway initiates PKC 
activation and Intracellular calcium release. Lithium inhibits the PI production 
which in turn decreases the intracellular calcium level and reduces excitatory 
toxicity. 
• Stimulating serotonin release from the hippocampus [14]: 
 
Lack of serotonin causes depression. Numerous in vitro and in vivo studies have 
shown that lithium stimulates release of serotonin (5-hydroxytryptamine, 5-HT) by 







Figure 1.6 Effects of lithium at microscopic level on neurotransmission and intracellular and molecular pathways 








1.4 Pharmacokinetics of Lithium: 
 
Lithium does not show any clinically significant protein binding properties. It is excreted 
almost entirely by the kidneys, with small amounts of leak in sweat and feces. Filtered lithium 
is reabsorbed substantially to make the clearance of lithium one fifth of clearance of creatinine. 
The rate of reabsorption is 70-80 percent in the proximal tubule of the kidney. Depending on 
age and Glomerular Filtration Rate (GFR), the elimination half-life of lithium is 18-24 hours 









2.1 Hypothesis Approach 
 
Lithium toxicity or Lithium overdose is the condition of having too much Lithium. It can 
occur due to excessive intake or decreased excretion. Lithium, absorbable by the 
gastrointestinal tract, is distributed to the body mostly in the kidney, thyroid, and bone but it is 
exclusively excreted by kidney and sweat. Chronic Lithium toxicity leads to severe 
complications like renal toxicity or failure, hypothyroidism and in rare cases it causes coma, 
heart failure or peripheral cardiovascular collapse, seizures, and death. The first aim of this 
literature is to determine safe dosage of Lithium for mammalian use. 
 
2.2 Lithium Toxicity 
 
Excessive intake or impaired excretion results in lithium accumulation which finally leads to 
Lithium toxicity. At therapeutic levels of 1 mM or less, lithium does not have significant 
myocardial effects. In 1985, Baandrup examined myocardial changes in rats with lithium- 
induced uremia [16]. The rats were treated for 6–12 weeks with lithium. They found that rats 
with uremic changes showed evidence of cardiac damage with infiltration of lymphocytes, 
histiocytes, and plasma cells. These changes were not present in rats that were not uremic. 
However, the changes were reversible. The authors concluded that presence of chronic kidney 
damage and lithium treatment together can lead to reversible myocardial changes. 
Prolonged exposures to a serum lithium level of 2 mM or greater may lead to liver and 




have alcohol dependence. In rats, superoxide dismutase (SOD) and glutathione peroxidase 
(Gpx) activity increased in the liver but not in the brain. Regular monitoring of serum 
concentrations of lithium is essential, particularly in patients with preexisting neurological 
illness, older age, or receiving medications that may interact with lithium. 
Long-lasting lithium intoxication can produce irreversible brain damage. Cerebellar 
symptoms, dementia, parkinsonian syndromes, choreoathetosis, brain stem syndromes, and 
other neuropathies may persist after stopping lithium treatment. Electroencephalographic 
changes may detect lithium intoxication despite moderate serum levels. 
 
 
2.3 Levels of Lithium Toxicity 
 
There is a very narrow gap between the therapeutic dosage and the toxic dosage of lithium. 
There are three stages of lithium toxicity. 
 
 
• Acute poisoning in previously untreated patients: 
 
Predominantly affects central nervous system (CNS). It is characterized by mild 
symptoms despite elevated plasma lithium level. However clinical features vary 
with the specific pattern of poisoning, symptoms may be minor. The delayed 
diffusion of lithium to the brain causes the absence or delayed symptoms. Mild 
lithium poisoning includes drowsiness, nausea, vomiting, tremor, hyper- 
reflexia, agitation, muscle weakness and ataxia. More prominent symptoms are 




• Acute-on-chronic poisoning in previously treated 
patients: Due to overdose. 
• Chronic poisoning in treated patients: 
 
It is caused by the progressive lithium accumulation due to renal dysfunction, 
low sodium intake and drug-drug interactions. It may result in severe 
neurological symptoms with plasma lithium level just above the therapeutic 
range. In most severe cases, it leads to convulsions, myoclonus, 
cardiopulmonary collapse, and coma. 
 
 
Serum lithium level is just a guide to the potential risk of lithium toxicity. The patient’s 
history, clinical findings and kidney functions should be considered before reaching a 
diagnosis. As the distinction between these three stages are subtle, it can be considered as a 
progression of potentially severe overdose. 
Severity of lithium poisoning can only be determined by presence of gastrointestinal 
symptoms. These symptoms are prominent in acute poisoning but almost absent in chronic 
toxicities. 
The stage of lithium toxicity can be determined by the gastrointestinal symptoms 














CNS (SEIZURES) delayed Common > 2.mmol/L 
 RENAL usually not significant universal  
   
 ECG normal QT prolongation usual 
THYROID none Hypothyroidism 20% 




2.4 Methods and Material 
 
For this experiment, neuronal cells were isolated from rat embryos. A Sprague Dawley E17 
pregnant rat was anesthetized with a combination of ketamine and xylazine according to the 
recommendations and guidelines of the Institutional Animal Care and Use Committee; after 
which the rat was pinned down and the abdomen was cut to expose the fetuses. Fetuses were 
removed one at a time, with the rest remaining in the live mother; the embryo was then 
extracted from the removed fetus. Holding the embryo in an upright position with the anterior 
portion of the head faced away, an incision was made along the midline of the skull with a 
scalpel. Next the skull was peeled back, and the cortices teased out. Successful extraction can 
be confirmed if the removed tissue has a kidney shape (Figure 3.1). Extracted hemispheres 
were placed in L-15 media (Thermo Fisher Scientific) on ice, finally meninges were removed. 
The entire extraction process, from administering anesthesia to removing meninges, was done 
in less than 10 mins. If many cells were needed, extractions were done by two or more 
technicians simultaneously to keep total extraction time under 10 mins. One pup with both 
cortices removed produced almost 2.5 million cells. The whole enzymatic tissue digestion, 
neuronal isolation techniques, cell count, and cell plating were performed as per our standard 
laboratory protocols. 
Neuronal cells were isolated from rat embryos and plated on 12mm poly-D-lysine 
coverslips (Corning; Teterboro, NJ, USA) at a density of 50,000cells/cm2 in cortical media. 
The cortical media was comprised of Neurobasal medium (Thermo Fisher Scientific; Fair 
Lawn, NJ, USA) with 1% Penicillin/Streptomycin (Thermo Fisher Scientific), 2% 50X B-27 
Supplement (Gibco, under Thermo Fisher Scientific), and 0.2% L-Glutamine (Sigma-Aldrich; 




days later, cells were treated with 100 mM glutamate for 24 hrs. The next day these cells were 
treated with different concentrations of Li (0.05 mM, 0.5mM, 1mM and 5mM respectively) 
again for 24 hours. Finally, these cells were observed under the microscope and analyzed for 
metabolic activity with an MTT assay. After more than 14 days in culture they lose quality 
and are no longer appropriate for experimentation. 
MTT assay quantifies level of metabolic activity in cells in culture and has been widely used 
to assess cell viability. It is a colorimetric reaction that can be easily from cell monolayers 
plated in the wells. Living cells reduce yellow tetrazole into purple formazan. For MTT assay 
supernatant was aspirated from each well. The plate was incubated at 37 degree Celsius for 
30-45 minutes after adding 100 ul of MTT solution (5 mg/ml MTT solution in 10% FBS in 
PBS) into each well. After incubation, the MTT solution was aspirated from each well. Before 
putting it into plate reader, the plate was kept at temperature for 15 minutes. Plate reader was 
set at 490 nm. 
 
 
Figure 2.1 Step-by-step procedure of neuronal dissection from freshly extracted fetus. a) Fetus removed from 
its embryonic sac. b) The embryo held with the brain facing up. The brain of an E17 pup has developed enough 
while the skull is thin enough so that the hemispheres can be easily distinguished. c) Incision along the midline 
of the skull being careful not to puncture the brain. d) Peeling back of the skull. e) Gentle back and forth teasing 
of the cortices from the brain. f) The final kidney shaped tissue extracts. 




2.5 Results and Analysis 
 
Table 2.2 MTT Assay - Absorbance of Lithium by cortical neural cells 
Condition Absorbance of lithium by 
cortical neural cells 
Standard error 
Control (no treatment with L- 
glutamate and LiCl) 
0.16565 0.01752 
Injury (treated with 100 mM 
L-glutamate but no LiCl 
treatment) 
0.16565 0.01833 
Treated with 100 mL L- 
glutamate and 0.05 mM LiCl 
0.1414 0.01858 
Treated with 100 mL L- 
glutamate and 0.5 mM LiCl 
0.1432 0.01453 
Treated with 100 mL L- 
glutamate and 1 mM LiCl 
0.15836 0.01643 
Treated with 100 mL L- 
glutamate and 5 mM LiCl 
0.10671 0.00686 
 
Primary culture of neuronal cells represented a nearly homogenous population of excitatory 
neurons. After 24 hours of exposure to toxic levels of 100 mM glutamate, the cells began 
showing signs of neurodegeneration. This was characterized by fragmentation of axonal 
projections and shrinkage of dendritic arborizations (Fig. 2.3b). On the other hand, the cells, 
categorized in several groups and treated with 0.05 mM/L, 0.5 mM/L, 1 mM/L and 5 mM/L 
along with glutamate showed significantly lower numbers of dead cells (Fig. 2.2). In addition, 
many axons remained intact and there were few signs of dendrite retraction (Fig. 2.3c-f). 
Incubation of culture for 24 hours, marked the lowest number of dead cells at 1 mM/L lithium 
concentration (Fig. 2.2). The number of live cells at the primary culture and the glutamate and 
1 mM/L lithium treated culture were not significantly different. Neuronal cells appeared 
similar in structure to those in the no lithium control (Fig. 2.3a). Therefore, 1 mM of lithium 
was found to be the optimal concentration for inducing neurotoxicity recovery. The MTT 






























Figure 2.2 Bar graph of cell metabolic activity results. 1 M produced activity closest to the control and was 
chosen as the working concentration for my experiments. Cell were cultured in a 96 well plate for 12 days before 
treatment. Cells were treated with a range of 0.05 mM-5 mM lithium in media for 24 hours prior to metabolic 
activity analysis with MTT assay. Top: Results obtained from the plate reader. 200 uL of solution was measured 
for each condition. Bottom: The percent difference from control. The relative difference of each condition from 












































Neuronal cell metabolic activity did not differ significantly among amount of lithium 
treatment after injury (one-way ANOVA, F (5,42) = 2.31, N = 8, ƞ2 = 0.11, p = 0.06). Post- hoc 
t-tests reveal no statistical significance difference between the control and 1 mM groups (t(8) 
= -0.26, p = 0.801), control and 0.05 mM group (t(14) = -1.13, p = 0.278), control and 0.5 mM 
group (t(14) = -1.19, p = 0.253), control and 1 mM group (t(14) = - 0.26, p = 0.801), control 
and 5 mM group (t(14) = -2.95, p = 0.011), injury and 0.05 mM group (t(14) = 0.97, p = 
0.350), injury and 0.5 mM group (t(14) = 1.43, p = 0.175), , injury and 5 mM group (t(14) = - 
1.43, p = 0.176), 0.5 mM and 0.05 mM group (t(14) = -0.13, p = 0.901), 1 mM and 0.05 mM 
group (t(14) = -0.66, p = 0.518), 5 mM and 0.05 mM group (t(14) = 2.21, p = 0.044), 1 mM 
 
and 0.5 mM group (t(14) = -0.65, p = 0.528), 5 mM and 0.5 mM group (t(14) = 3.08, p = 
0.008), 1 mM and 5 mM group (t(14) = 2.12, p = 0.052). However, statistical significance 
difference was found between the control and injury group (t(8) = 3.59, p < 0.003) and between 
injury and 1 mM group (t(14) = 3.77, p = 0.002). 1 mM lithium was chosen as the working 








Figure 2.3 : The figures above represent neurons in cell culture study with and without glutamate-induced injury 
and after treatment with LiCl at different concentrations. 
A) Neural cell culture without any treatment. B) Neural cell culture with glutamate treatment. C) Neural Cell 
culture with 0.05 mM LiCl. D) With glutamate and 0.5 mM LiCl. E) With glutamate and 1 mM LiCl. F) With 






The above experiment demonstrated that at 0.05 mM and 0.5 mM concentration, lithium 
protecting neurons against glutamate-induced toxicity. But at 1 mM concentration, lithium is 
showing maximal effect, the number of neurons in the culture treated with glutamate and 
lithium is closest to the culture without any treatment. In this concentration, neurons behaved 
like neurons without injury or lithium because they had similar levels of metabolic activity and 
similar structural integrity, i.e., long, intact, and thick axon projections as well as undisturbed 
dendritic arbors. Thus, protection was observed at 0.05 mM and 0.05 mM, however significant 
protection was achieved at 1 mM (Fig 2.3). This experiment also showed that at a 
concentration of 5 mM lithium, it loses its neuroprotective action. From this study, I have come 
into conclusion that the lithium achieves maximal neuroprotectivity at 1 mM concentration and 
also lithium has a very narrow therapeutic range and above that level, lithium loses its 
neuroprotective nature and becomes toxic. Quantification of neuronal survival by MTT assay 
revealed neuroprotectivity of lithium is unchanged while the glutamate concentration that 
induced the injury remains the same. The large differences in standard errors between replicas 









3.1 Hypothesis Approach 
 
Recent studies demonstrate that Lithium has robust neuroprotective effects. It is reported that 
lithium protects neural cells against apoptosis induced by a variety of insults, for example, 
deprivation of high potassium, withdrawal of growth factors on cultured neurons and neutrally 
related cells. The mechanism of lithium for neuroprotective effects are not clear yet, but 
cellular and molecular studies suggest the neuroprotective mechanism against glutamate 
excitotoxicity due to inhibition of N-methyl-D-aspartate (NMDA) receptor activity. This 
literature observes the healing effect or neuroprotective effect of Lithium by running histology 
on the blood samples taken from time dependently lithium treated rats after induced mild 
traumatic injury. 
 
3.2 Neuroprotective Effects of Lithium 
 
From the previous study, lithium has shown neuroprotective effect at a narrow range of dosage 
on neurons against glutamate-induced toxicity. This result is also supported by several in vitro 
and in vivo studies which documented a neuroprotective effect of lithium against various 
noxious insults by preventing apoptosis through multiple mechanisms [18]. In the lithium- 
pilocarpine model [19], a long-standing model of status epilepticus, Wister rats were injected 
with lithium (3 mEq/kg) intraperitoneally 19 - 24 hours prior to the administration of 
pilocarpine (30-60 mg/kg) to induce consistent status epilepticus (SE). The mortality rate of 




compared to the rats who were subjected to a high dosage of pilocarpine without lithium [20]. 
Another study by Chen and Chuang [21] showed that the expression of p53 and Bcl-2, 
by lithium treatment, causes neuronal survival. Chen et al [22]., showed the chronic 
administration of two structurally dissimilar mood stabilizing agents, lithium, and valproate 
results in increased Bcl-2 levels in the cortex, with beneficial neuroprotective effects. High 
levels of Bcl-2 may be due to the inhibition of GSK-3 which is caused by Lithium. Aside from 
the antiapoptotic effect of Bcl-2, it stimulates the regeneration of axons post injury [23]. 
At the cellular level, lithium shows protective quality against neuronal apoptosis and 
glutamate excitotoxicity [24]. Lithium at a low dosage protects cerebellar neurons against 
glutamate excitotoxicity by inhibition of NMDA receptor mediated calcium influx. Study by 
[25]has shown that glutamate excitotoxicity was blocked by NMDA receptor antagonists (MK-
801 and AP5) but not by non-NMDA receptor antagonist (NBQX) which supports the theory, 
glutamate induced toxicity is exclusively dependent on NMDA receptor subtype. Also, MTT 
assay quantifies neuronal survival in presence of lithium is independent of glutamate 
concentration [25] and is due to pre-treatment with 1mM LiCl. 
GSK-3, a serine/threonine kinase, plays pivotal role in several cellular processes like 
gene transcription, cell apoptosis, glycogen synthesis and directly regulates several 
neurotransmitter systems like dopaminergic, glutamatergic, serotonergic, and cholinergic. 
Evidence shows that inhibition of GSK-3 by dose-dependent lithium treatment is a result of 




According to the inositol depletion hypothesis [26], lithium also could exert its 
therapeutic effects through the phosphatidylinositol (PI) pathway by direct inhibition of IMP 




Figure 3.1 The figure depicts several pathways of neuroprotective mechanisms of lithium. Lithium 
downregulate GSK-3 activity by directly inhibiting ATP/Mg2+ dependent catalytic activity of GSK-3 and via 
Ser-phosphorylation od GSK-3, several factors including PI3K/Akt pathway which can be activated by lithium. 
By upregulating phosphorylation of NMDA receptors, lithium gives protection against glutamate- induced 
excitotoxicity. These lithium induced events lead to changes in transcriptional factors like CREB, 
neuroprotective genes (Bcl-2 and BDNF). 




3.3 Methods and Materials 
 
6-8 weeks old male Sprague-Dawley rats were purchased from Charles River laboratory 
(Wilmington, MA). Animals were maintained in sterile cages under pathogen free conditions 
in accordance with institutional ethical guidelines for care of laboratory guidelines, National 
Institute of Health guidelines and the Institutional Animal Care Use Committee, Rutgers 
University. Animals were randomly distributed in 4 experimental groups (3 rats/group): 1) 
Control (went under surgery but not injured nor administered Li), 
2) Treated with 1mM LiCl, 3) Injured and 4) Injured with 1 mM LiCl. The 4th group were 
further categorized into 3 subgroups: a) 24 hours post injury with 1 mM LiCl treatment, b) 72 
hours post injury with 1 mM LiCl treatment and c) 1-week post injury with 1 mM LiCl 
treatment. An optimal dose concentration of LiCl (mM) was determined from the previously 
performed dose dependent study on cortical neural cells. 
After TBI, the human brain goes through several complex changes, which cannot be 
replicated by any single model under laboratory environment. But several preclinical models 
of TBI have been developed and successfully implemented to study its underlying pathology. 
The fluid percussion injury (FPI) model (Amscien Instruments) is the most commonly used 
animal model of TBI because of its capability to produce diffusion (midline FPI) and mixed 
(focal and diffuse; lateral FPI) which mimics very closely the pathology that are frequently 
seen following human TBI. Principle of FPI is based on generation of fluid pressure pulse on 
the intact dura through a craniotomy by striking the piston of a fluid reservoir with the help of 
a pendulum. FPI models can produce mild, moderate, and severe injury depending on the 




For this experiment, the rats were anesthetized with a mixture of ketamine and 
xylazine (10:1 (100mg/10mg/kg), 0.1 mL/100g) and placed in a stereo taxic frame before 
craniotomy. Rat brain craniotomy is performed as described by Alder J. et. al [28] On the left 
parietal skull, 2.5 mm lateral from the sagittal suture and 3.0 mm caudal from coronal suture, a 
3 mm hole was made by drilling, maintaining the dura intact. A luer-lock hub was glued on the 
skull over the exposed dura with cyanoacrylate gel and secured by application of methyl- 
methacrylate (Henry Schein, Melville, NY, USA). 24 hours after surgery the rats were again 
anesthetized by isoflurane to receive lateral FPI (1.3 – 1.8 atm). 5 minutes after the injury, 1 
mM LiCl (15 mg/500g) was injected intraperitoneally. The animals were observed for 24 
hours, 72 hours and 1 week. Following FDA drug dosage guidelines, each lithium treated rat 
was given 15 mg/500kg LiCl/day everyday intraperitoneally till euthanization. 
 
Animals were sacrificed after 24 hours, 72 hours and 1 week after the injury to harvest 
the brain tissue for analysis and collect blood samples. An hour before euthanization, rats were 
anesthetized as describes above to inject 1 uL of fluorescent label tracer (dextran-conjugated 
Fluorescein, 3000 MW) intracisternally into the blood parenchyma [29]. 
 
To collect the blood an incision was made on the left side of the chest to cut through the 
diaphragm, from the top of the sternum, and peeled back the chest to expose the heart. A 22- 
gauge needle was inserted attached to a syringe into a ventricle of the heart. Slowly the 
plunger was pulled off the syringe to withdraw the blood slowly to prevent the heart from 
collapsing. 1 mL of blood was collected and let it sit at room temperature for 1 hour for blood 
to clot. After centrifuging blood for 20 mins at 2200 RPM supernatant (serum) was collected 




uL serum was added into a 96 well plate and measured with a fluorescent plate reader at 
521nm emission and 494nm excitation. 
Animals were sacrificed after 24 hours, 72 hours and 1 week after the injury to harvest 
the brain tissue for analysis and collect blood samples. Brain tissues were immersed in 4% 
paraformaldehyde overnight, followed by cryoprotection in 30% sucrose in PBS until sink. 
Brain tissues were snap frozen in Tissue-Tek OCT compound (Thermo Scientific, Rockford, 




Figure 3.2 Gross observation of injured brain. Pathomorphological changes in rat brains at different 
pressure induced by Fluid Percussion Injury. 




Histological Staining  
 
Brain tissue sections were stained with Cresyl Violet to count the cells. The Cresyl Violet is a 
basic dye, and is a common stain used in histology. Cresyl Violet is used to stain the neurons 
in the brain and spinal cord. 
Chemicals needed : 0.1% Cresyl Violet Acetate; Ethanol in different concentration - 30, 70, 
90 and 100%; Xylene (Fisher Scientific - catalog #HC700 - 1 Gal); DPX mountant (Fluka 
Biochemicals - catalog #44581 - 100 ml); Glacial Acetic Acid; Distilled water Solutions : To 
make Cresyl Violet stain - 500 ml distilled water, 0.5 g cresyl acetate, 1.25 ml Glacial acetic 
acid (2.5 ml 100% GAA in 1 L of H2O); were stirred on heat (60 degrees Celsius) until 
majority of the crystals are dissolved. The solution was cooled down and filtered before every 
use. 
Staining procedure: The brain sections were stained in 0.1% Cresyl Violet solution for 2 
mins and then rinsed quickly in distilled water a few times. Then the slides were dipped into 
30, 70, 90 and 100% ethyl alcohol respectively for 30 seconds each time. Then the slides were 
cleared in Xylene for 3 minutes before mounting with DPX mounting medium. Imaging: 
Whole brain tissue sections images were scanned (20x magnification) by Leica Aperio Versa 
200 digital pathology grade slide scanner. Three regions (200X200 um) per tissue slices (2 
slices per animal) in the side of injury (motor cortex) are selected to count the number of 
Cresyl violet labeled neurons using counter tool in ImageScope. Location and size of region 




3.4 Results and Analysis 
 









Pure Control without LiCl 
and without injury 
3 24 hours 
Group 
2 
Control with LiCl without 
injury 
3 24 hours 
Group 
3 
Control with injury and 
without LiCl 
3 24 hours 
Group 
4 
Injury with LiCl 9 a) 3 animals for 
24 hours 
b) 3 animals for 
72 hours 
c) 3 animals for 1 
week 
 
Table 3.2 Absorbance values of tracer in rats that have undergone mild traumatic brain 
injury and lithium treatment. 
 
Condition Rat 1 Rat 2 Rat 3 Mean 
Control + Li 26358414 24247500 24611480 25072465 
24 hr after Injury + Li 69528048 67351672 68337408 68405709 
72 hr after injury + Li 45686524 42946336 38663728 42432196 








Figure 3.3 : Tracer level in the brain sections with A) Control, B) Injury, C) 72 hours post-injury with LiCl, 




Release of labeled tracer differed significantly among length of lithium treatment after injury 
(one-way  ANOVA,  F  (3,8)  =  307.7,  N  =  3,  ƞ2         =  0.27,  p  <  0.001).  Presence  of  tracer 
corresponds to the leakiness of the brain parenchyma. Post-hoc independent samples t- tests, 
with Bonferroni correction (α adjusted to 0.008), revealed significant differences between the 
control+lithium and 24 hrs after injury+lithium groups (t(4) = 47.84, p < 0.001), 
control+lithium and 72 hrs after injury+lithium groups (t(4) = 8.09, p = 0.001), 24 hrs after 
injury+lithium and 72 hrs after injury+lithium groups (t(4) = 12.15, p < 0.001), 24 hrs after 
injury+lithium and 1 week after injury+lithium groups (t(4) = -48.92, p < 0.001), and 72 hrs 
after injury+lithium and 1 week after injury+lithium groups (t(4) = - 7.81, p = 0.001) but not 
between the control+lithium and 1 week after injury+lithium groups (t(4) = 0.82, p = 0.459). 
This demonstrates that continual treatment with lithium for 1 week significantly improved the 








Figure 3.4 Bar graph of plasma results. The amount of tracer in the blood plasma was not significantly 
different between the no injury and treatment with lithium for 1-week groups. Top: Percentage of tracer 
compared to the no injury control. Each treatment was compared to the no injury control. Graph shows 
significant decreases in tracer levels with subsequent longer treatments of lithium. Bottom: The level of tracer 
in circulating blood. After designated treatment lengths, rats were sacrificed, and blood was immediately 
collected from the systemic circulation. Serum was removed and 20 uL was analyzed by a fluorescent plate 






Figure 3.5 Scanned images of a brain section showing the Cresyl violet stained cells Top : 3 regions in the cortex area of a whole 
brain section were selected for analysis of this study Bottom : Three region at 50x magnification, showing the individual neuronal 






Figure 3.6: Representatives figures showing the cell count in a region in a whole brain section for each condition 





























Fig 3.7 Bar graph of cell count. There is a distinct difference between the number of cells in the brain tissue 
sections (coronal plane) of control animal and injured animal. With LiCl treatment post injury, an increase in 
number of cells. 
 
 
Count of crystal violet labeled cells differed significantly among length of lithium treatment 
after injury (one-way ANOVA, F (4,10) = 15.45, N = 3, p < 0.001). Post-hoc independent 
samples t-tests, with Bonferroni correction (α adjusted to 0.005), revealed significant 
differences between the control and 72 hours treatment groups (t(4) = -6.10, p < 0.004), and 
lithium and 72 hours treatment groups (t(4) = -10.96, p < 0.001) but not between control and 
lithium groups (t(4) = 2.10, p = 0.104), control and injury only groups (t(4) = 5.36, p > 0.005), 
control and 1 week treatment groups (t(4) = -4.1, p = 0.015), lithium and injury only groups (t(4) 
= -5.05, p > 0.007), lithium and 1 week treatment groups (t(4) = -3.49, p = 0.025), injury only 
and 72 hours treatment groups (t(4) = 1.71, p = 0.163), injury only and 1 week treatment 
groups (t(4) = 1.49, p = 0.21), or 72 hours treatment and 1 week treatment groups (t(4) = 
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Due to rupture of BBB resulting from FPI, a high level of FITC tracer accumulation was 
expected which is observed by injecting large molecular weight tracer like FITC into the CSF 
[31]. As expected, the results show a significant difference between tracer level in injured and 
control animal which can be decreases by the LiCl treatment (Fig. 3.1). In the above graph 
(Fig 3.2), indicating very less or almost no significant difference between the tracer level 
between control and treatment with LiCl for a week group, even though after 24 hours and 72 
hours an increase of tracer level was seen. Small level of tracer signifies less leakage of tracer 
into the circulation because the blood-brain barrier and in extent, the central nervous system 
are intact and not damaged. Due to natural healing nature of BBB, this study alone cannot 
conclude the neuroprotectivity of neurons after TBI. 
 
To support the observation of the tracer level, a quantitative study was performed. An 
examination of Cresyl Violet stained sections produces a clear demonstration of neuronal loss 
post FPI. As shown in Fig 3.3, LiCl treatment resulted in a time dependent cell number 
increase post FPI injury. The difference in the number of cells in the FPI injured animal (Fig 
3.3 C) as compared to the control animal or the animal treated with LiCl without FPI (Fig 3.3 
A & B) reversed with treatment of LiCl post FPI for 72 hours and 1 week (Fig D & E). This 
result demonstrated the neuroprotectivity of lithium brain post injury. These findings may 







Considering the clinical application of lithium for several neurodegenerative and central 
nervous system diseases, this literature has investigated the effects of lithium as a protective 
agent against various insults resulting in serious brain injury. 
Recent studies by [24] have shown neural survival in rat cerebral cortical cultures 
treated with 1 mM LiCl for 5-6 days against excitotoxicity of 8-10 uM glutamate. The study 
had marked significant protection at 0.2 mM and virtually complete protection at 1 mM. 
Cerebral cortex being the primary target in the brain involved in the therapeutic actions of 
lithium. The study also demonstrated less significant neuroprotection at or below concentration 
0.6 mM while declined at a dose higher than 1.2 mM which could be related to lithium toxicity. 
 
In another similar study [27], primary culture of cerebellar granule cells was exposed to 
glutamate insult through activation of NMDA receptors. Rat cerebellar cells were treated with 
glutamate for 24 hours and preincubated for 7 days with 2 mM LiCl. The study showed that the 
degree of protection depends on the preincubation time and lithium concentration. For this 
experiment, the significance was detected at 0.5 mM and the maximal effect was observed at 3 
mM. From all the experiments and data, it can be concluded that the lithium protection against 
glutamate toxicity occurs within the therapeutic range i.e., 0.5-1.5 mM. 
The blood brain barrier (BBB) is formed by a highly selective semipermeable 
endothelial cells that prevents circulating toxins or pathogens in the blood to reach central 
nervous system while at the same time allowing vital nutrients to enter the brain. The 
breakdown of BBB causes neuroinflammation and neurodegeneration which contributes to 




-ain causing cortical, subarachnoid hemorrhage (SAH) contusion, subdural and epidural 
hematomas. Animal model FPI, produces similar damages to the brain as observed in TBI 
patients such as focal contusions, petechial intraparenchymal hemorrhages, SAH and axonal 
injury [33]. Therefore, level of tracer in the circulation signifies disturbance of the blood-brain 
barrier. Thus, measuring the tracer level in the CSF will give a vague idea about lithium’s 
protection against FPI at its therapeutic level as established by the previous study [34]. 
According to the experimental data performed for this thesis, the leakage of tracer in the blood 
diminishes with prolonged treatment with LiCl post injury. 
Nissl-stained sections quantified the cell loss and how lithium affects neurons post 
injury [35]. This data reveals that lithium can be used for clinical treatment of TBI as it shows 
promising effect on protection of neural cells. Various studies have found lithium to be 
protective against glutamate excitotoxicity [24], TBI induced neuronal degeneration [18] and 
this neuroprotection associated with a wide range of factors like GSK-3, PI3K/Akt [36], Bcl-2, 






Along with neuroprotective properties of lithium, several preclinical studies have shown that 
lithium treatment promotes neurogenesis post injury [38]. Injured nerve cells undergo 
apoptosis which is caused by several factors. One aspect that highly contributes to cell death is 
low level of Bcl-2 which has capacity to regenerate cells after injury. Huang et al. [39] studied 
the regeneration assay model which shows survival of cultured retinal ganglion cells and its 
neurite number and length of regenerating retinal ganglion cells associated with up-regulation 
of Bcl-2 upon treating with lithium (0.5-5 mM for 5 days). 
In a preclinical study on rodent quinolinic acid induced striatal injury model, Chuang 
et. al [38, 40]has demonstrated short term lithium exposure promotes proliferation of cells of 
astroglial and neuronal phenotypes i.e., neural stem cells. In the adult brain, neural stem cells 
are located in subventricular zone. BrdU labeling in lithium treated injured striatum revealed a 
large number of proliferating BrdU labeled cells near the quinolic and injection sites following 
reduction of BrdU cells in the subventricular area. 
Understanding the mechanism by which lithium can induce neurogenesis, has evolved 
since the discovery. In 2007, Silva et. al [41] found in lithium treatment reversed the effect of 
chronic mild stress in rats which led to decreased hippocampal cell proliferation. The stress 
increased GSK-3B protein expression. Lithium by inhibition of GSK-3B blocked the negative 
effects of chronic mild stress on behavior and cellular functions. 
In vitro rat spinal cord model reported enhancement of cell proliferation and neuronal 
production of neural progenitor cells after transplantation in presence of lithium [42]. Lithium 




-vents differentiation, through gain control pathway. GSK-3B phosphorylates and inhibits 
Notch [43]. Lithium by inhibition of GSK-3B, indirectly helps to disinhibit Notch. 
More recent studies indicate that the lithium effect on hippocampal neurogenesis 
requires Wnt/B-catenin activation due to GSK-3B inhibition. In study by Wexler el. Al [44] in 
2008, it has been reported that the lithium stimulates proliferation of adult hippocampus 
progenitor cells at therapeutically relevant doses. These effects are independent of IMP but 
depend on Wnt pathway and inhibition of GSK-3B. For example, RNAi inhibition of B- 





Figure 5.1 GSK-3 regulates Wnt and Akt-dependent signaling. Akt is activated by growth factors including 
neureotrophins, which in turn inhibits GSK-3 by phosphorylation allowing activation of factors which promote 
cell growth. Wnt target genes promote neurogenesis which is activated by inhibition of GSK-3 within the Axin 
complex stabilizing b-catenin. Lithium activates Wnt/b-catenin which stimulates neurogenesis and cell growth. 




In summary, recent studies of lithium at a preliminary level, has demonstrated robust 
beneficial effects in experimental models of TBI not just by preventing cell loss or 
neuroprotectivity but also stimulating cell growth, taking part in neurogenesis actively. By 
controlling several factors which promotes cell growth, lithium enhances the cell growth 
especially the regeneration of axons in the mammalian Central Nervous System (CNS), 
neurite outgrowth and increases axonal growth rate. Further research on lithium will raise the 
possibility of lithium to be used in clinical settings as a treatment for compensation of neural 
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